戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n and adjuvant kinetics may enable increased vaccine potency.
2 ve MHC I and II processing could enhance DNA vaccine potency.
3 pe I IFN-STAT1 signaling pathway may enhance vaccine potency.
4 an apparent 50- to 200-fold increase in pDNA vaccine potency.
5  activate the type I IFN pathway may enhance vaccine potency.
6 n-presenting cells in vivo to enhance cancer vaccine potency.
7 ng antigen to the centrosome can improve DNA vaccine potency.
8  priming of antigen-specific T cells and DNA vaccine potency.
9  MHC class I presentation of antigen and the vaccine potency.
10 esents an innovative approach to enhance DNA vaccine potency.
11 ance of immune evasion molecules in reducing vaccine potency.
12 mbrane protein type 1 (LAMP-1), enhanced DNA vaccine potency.
13 ht be a promising strategy for improving DNA vaccine potency.
14 thus provide a unique approach for enhancing vaccine potency.
15 ides the opportunity to enhance RNA replicon vaccine potency.
16 eading VP22(1-267) mutants failed to enhance vaccine potency.
17 oparticles is a powerful means of increasing vaccine potency.
18 rial toxin to an antigen may greatly enhance vaccine potency.
19 ase primary SAM expression and the resulting vaccine potency.
20 e vaccine formulations and routes to improve vaccine potency and breadth.
21  AnAPN1 TBV antigen and report on its marked vaccine potency and immunogenicity, its capacity for eli
22 ng tumor cell vaccine significantly enhances vaccine potency and may represent a potential new approa
23 ess several limitations, including enhancing vaccine potency and reducing toxicity.
24 re being developed as a means for addressing vaccine potency and viral heterogeneity.
25 ion in the genital tract, develop assays for vaccine potency, and understand enough about the epidemi
26 -radial immunodiffusion (SRID), the accepted vaccine potency assay.
27 s type 1 (HSV-1) VP22 protein to enhance DNA vaccine potency because DNA vaccines lack the intrinsic
28  2019, strategies can now focus on improving vaccine potency, breadth, and stability.
29 terferon genes (STING) agonists, can enhance vaccine potency but risks systemic toxicity and improper
30 so evaluated the feasibility of enhancing DC vaccine potency by SRA/CD204 blockade.
31              We have previously enhanced DNA vaccine potency by targeting antigen to MHC antigen pres
32 ogen interactions, therapeutic side effects, vaccine potency evaluation, and crosstalk between system
33 his NasRED-nAb assay applicable to measuring vaccine potency, immune responses to infection, and the
34  found that linkage to CPPs enhanced peptide vaccine potency in vivo by as much as 25-fold.
35 ch that has been explored to enhance peptide vaccine potency is covalent conjugation of antigens with
36                                    Measuring vaccine potency is critical for vaccine release and is o
37                             The assurance of vaccine potency is important for the timely release and
38 ccines against biological toxins is that the vaccine potency is often limited by lack of antigenic br
39 uations during vaccine transport could cause vaccine potency loss that could go undetected.
40                   This demonstrates that DNA vaccine potency may be augmented by the incorporation of
41  of nano-vaccinology to intensify the cancer vaccine potency may overcome the need for administration
42 e potential to provide an adjuvant effect on vaccine potency, or, conversely, it might establish a te
43                                Enhancing DNA vaccine potency remains a challenge.
44 for anthrax pathogenesis studies and anthrax vaccine potency testing, is a good candidate for such an
45 nce antigens containing HA used in influenza vaccine potency testing.
46 tion, they provide a rationale to enhance DC vaccine potency through SRA/CD204-targeting approaches t
47 55S) allele conferred significantly enhanced vaccine potency to KBMA vaccines.
48 e, potentially universal strategy to enhance vaccine potency, via intralymph node (i.LN) injection.
49                                     Improved vaccine potency was associated with an increase in tumor
50 te the impact of administration route on RNA-vaccine potency, we investigated the immunogenicity of a
51 four-amino-acid LRMK modification, increases vaccine potency when compared with unmodified class II e
52 ically facilitate SLAM signaling may improve vaccine potency when targeting HIV Ags specifically, as
53                         The need to optimize vaccine potency while minimizing toxicity in healthy rec
54 d adjuvant compounds to LNs can also enhance vaccine potency without sacrificing safety.
55 ence, a rational strategy for increasing DNA vaccine potency would be to facilitate both pathways.